Durable Response News Today

Mind Medicine Inc. , , a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present detailed results from its...

A key opinion leader explores the integration of bispecifics into MM therapy regimens.

Rafael Fonseca, MD, discusses findings from the PERSEUS trial presented in December at ASH 2023.

Laurie Sehn, MD, discusses recent data on zanubrutinib, a BTK inhibitor, as third-line and beyond therapy for FL.

Read trending news, stories and press releases from PMN Wire News about Canadian and international businesses.

NovalGen announces one oral and one poster presentation at the 65th American Society of Hematology Annual Meeting...

Overall response rate (ORR) greater than 50% across three assessment criteria Median duration of tovorafenib treatment of 15.8 months as of June 5, 2023,...

Overall response rate greater than 50% across three assessment criteria Median duration of tovorafenib treatment of 15.8 months as of June 5, 2023, with 66% of patients remaining on treatment FDA...

-- In Three-Year Follow-up in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia, Tecartus Shows High Rates of Durable Response (CR+CRi 71%) and a Median Overall Survival of 26 Months

- Cryopreserved, Post-thaw CAR T Cell Composition and Effective CAR T Cell Dose are Predictive for Response to Treatment with Azer-cel- Peak CAR T Expansion, a Key Determinant of Durable Response, Strongly Correlated with Effective CAR T DoseDURHAM, N.C.--(BUSINESS WIRE)--$DTIL #ARCUS--Precision BioSciences (Nasdaq:...